MD/DPhil student @RDMOxford @UniofOxford. Tweets about medicine and bioengineering. Opinions are my own. 🇮🇩 🇬🇧
Oxford, England
Joined July 2017
- Tweets173
- Following187
- Followers130
- Likes358
Muhammad Hanifi retweeted
Today we report in @ScienceMagazine a one-time base editing treatment for Spinal Muscular Atrophy (SMA), the leading genetic cause of infant mortality worldwide, affecting ~1 in 10,000 births. science.org/doi/10.1126/scie…
PDF: drive.google.com/file/d/1H1k…
1/17
A clever strategy to build a synthetic 'organelle' in prokaryotes to run a custom biological pathways.
Also it started as an iGEM project! They really show you how far iGEM projects can go.
(1/4) Bacteria cannot have organelles in the sense as eukaryotes?
Old textbooks are WRONG!
Here we built the first synthetic organelle in bacteria, with RNA #PhaseSeparation, now published on Cell @CellCellPress.
#syntheticbiology #biocondensate cell.com/cell/fulltext/S0092…
Muhammad Hanifi retweeted
Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams.
Happy to share our bench>bedside journey
1/10
Muhammad Hanifi retweeted
Fantastic study from @lab_marine on the cellular hierarchy that governs melanoma growth and metastasis demonstrated by lineage tracing. Congratulations to all the authors and very honored to be part of this beautiful study. nature.com/articles/s41586-0…
Muhammad Hanifi retweeted
Are you 'Excited to share my new paper!'
Harsh truth:
Most people don't care
5 tips on how to tweet about your new paper to get real engagement
@OpenAcademics @PhD_Genie @PhDVoice @AcademicChatter
Muhammad Hanifi retweeted
Enjoyed this🧵?
Please RT the first tweet.
And follow me @LNivisonSmith if you are interested in
- macular degeneration research
- #WomeninSTEM
- #scicomm
- musings from a mother trying to survive #academia
Muhammad Hanifi retweeted
CRISPR can cut DNA and RNA, but did you ever wonder other activities might exist? Today in @biorxivpreprint, we show that the Type III-E Cas7-11 system programmably activates a nearby protease as part of microbial defense. + @jgooten @hnisimasu 🧵👇🏼biorxiv.org/content/10.1101/… 1/9
Muhammad Hanifi retweeted
Today we share in @NatureProtocols detailed strategy and experimental procedures for designing and executing prime editing (and twinPE) experiments in mammalian cells. Congrats Jordan, @AlexanderASousa, Peyton, and @PeterJ_Chen for this thorough analysis.
drive.google.com/file/d/12oI…
Muhammad Hanifi retweeted
Delighted to announce that our portfolio company
@Miro_Bio is to be acquired by @GileadSciences for approximately $405 million.
Read our full press release to learn more ⬇
bit.ly/3zzzJ2i
Muhammad Hanifi retweeted
RNA therapeutics landscape (private and public). From Cowen's recent RNA review.
Muhammad Hanifi retweeted
How did idea for @VerveTx come about?
👇
(L) April 2016, our response to @American_Heart One Brave Idea grant competition looking for coronary heart disease cure
(R) Our proposed timeline from then, dose first patient in ~5y
And (despite not getting award), right on time 😊
Muhammad Hanifi retweeted
Preprint alert 🚨:
#AAV vectors are one of the leading platforms for gene delivery for the treatment of human genetic diseases. Despite some clinical successes, AAV-based gene therapy still faces several challenges. biorxiv.org/content/10.1101/…
Muhammad Hanifi retweeted
The cost of living crisis in the UK has severely impacted post-graduate researchers. This is an open letter to the UKRI petitioning for the support of an increase to their stipend. Please support and share!
docs.google.com/document/d/1…
15 years ago, probably no one would have thought that we will have a therapeutic gene editing by 2022.
But here we are, with Verve and Beam testing a drug that could edit a part of the human genome to give people a 'superpower' (i.e. lower risk of cardiovascular events).
This Post is from an account that no longer exists. Learn more
Muhammad Hanifi retweeted
Genome editing for potential definitive treatment or curies for many genetic conditions is moving forward at high velocity. A new @CellCellPress review is a masterful state-of-the-science for delivery
cell.com/cell/fulltext/S0092… @davidrliu @samagyabanskota @liugroup @broadinstitute
Muhammad Hanifi retweeted
The peer-reviewed version of DNA Ticker Tape (now “DNA Typewriter”) is out today! During revision, we have expanded our lineage recording demonstration by integrating DNA Tape recording with single-cell RNA-seq (1/8)
nature.com/articles/s41586-0…
Muhammad Hanifi retweeted
Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy but the molecular basis for neurocognitive defects in DM1 patients is unknown. Excited to share our cover work where we generated 3D cortical organoids from DM1 patients.
science.org/doi/10.1126/scit…
It's been a huge privilege to do my DPhil alongside fantastic labmates, collaborators, and mentors at @MRC_WIMM and @OxPaediatrics. Pushing the last mile for the paper and can't wait to bring this tech from bench to bedside.
@TSS_Lab @rinaldi_ca @RDMOxford
Very proud of my fantastic student @_muhammadhanifi who has just won 2022 Ita Askonas Medal! Bravo Hanifi! @TSS_Lab @MRC_WIMM @RDMOxford
Muhammad Hanifi retweeted
'A complete remission in every single patient is “unheard-of”'
Combining genomics diagnosis of mismatch repair deficient + PD-1 immunotherapy led to complete remission of 18 consecutive patients w/ advanced colorectal cancer nejm.org/doi/full/10.1056/NE…
nytimes.com/2022/06/05/healt… #ASCO22
